ISR048

ISR048 is an investigational gonadotropin-releasing hormone (GnRH) agonist being developed by ISR Immune System Regulation Holding AB as an immunomodulatory therapy for chronic viral infections, with a primary focus on HIV. ISR positions ISR048 as part of a broad-spectrum antiviral platform, aiming to modulate the immune system rather than directly target viral proteins.[1][3][9][5][7][10] In a Phase IIa clinical study in HIV-infected patients on standard antiretroviral therapy, ISR048 is administered in addition to ART to explore whether transient GnRH agonism can enhance immune-mediated control of HIV reservoirs and improve virologic outcomes.[5][7][10] Detailed molecular structure, exact GnRH agonist identity, and full clinical data have not been publicly disclosed, and ISR048 remains an early-stage, company-specific code-name program without regulatory approvals.